Federally Funded Clinical Trials
Our research sites continue to participate in Federally-funded research through NRG Oncology. The following protocols are currently open to accrual. Please visit the CTSU members' website for full information about these protocols.
NSABP B-51
Protocol Activation (Date Opened to Accrual): 08/22/2013
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
ClinicalTrials.gov Identifier: NCT01872975
NSABP B-52
Protocol Activation (Closed to Accrual)
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
ClinicalTrials.gov Identifier: NCT02003209
NSABP B-53/SWOG S1207
Protocol Activation (Date Opened to Accrual): 09/03/2013
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
e3 Breast Cancer Study - evaluating everolimus with endocrine therapy
ClinicalTrials.gov Identifier: NCT01674140
NSABP B-55/BIG 6-13
Protocol Activation (Date Opened to Accrual): 07/03/2014
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
ClinicalTrials.gov Identifier: NCT02032823
NRG - BR003
Protocol Activation (Date Opened to Accrual): 06/26/2015
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
ClinicalTrials.gov Identifier: NCT02488967
NRG - GI002
Protocol Activation (Date Opened to Accrual): 10/12/2016
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
ClinicalTrials.gov Identifier: NCT02921256
NRG - BR005
Protocol Activation (Date Opened to Accrual): 04/13/2017
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery